Trial record 4 of 361 for:    Cerebral Arteriosclerosis

Reducing Total Cardiovascular Risk in an Urban Community (COACH)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Jerilyn K. Allen, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00241904
First received: October 17, 2005
Last updated: February 24, 2014
Last verified: February 2014
  Purpose

PLEASE NOTE: THIS STUDY IS ONLY ENROLLING PATIENTS CURRENTLY BEING TREATED AT BELAIR-EDISON FAMILY HEALTH CENTER.

The purpose of this study is to compare the clinical effectiveness and cost effectiveness of two cardiovascular risk reduction programs - a comprehensive intensive (Cl) intervention with a less intensive (LI) intervention - in African American, and white low-income patients with known excessive cardiovascular disease risk.


Condition Intervention
Cardiovascular Diseases
Heart Diseases
Coronary Disease
Diabetes Mellitus
Atherosclerosis
Cerebral Arteriosclerosis
Hypertension
Behavioral: Lifestyle Changes
Drug: Antiplatelet Agents
Drug: Beta Blocker
Drug: ACE Inhibitors

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Reducing Total Cardiovascular Risk in an Urban Community

Resource links provided by NLM:


Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • LDL-C [ Time Frame: Measured at 1 year ] [ Designated as safety issue: No ]
  • Blood pressure [ Time Frame: Measured at 1 year ] [ Designated as safety issue: No ]
  • HbA1c, if diabetic [ Time Frame: Measured at 1 year ] [ Designated as safety issue: No ]
  • Physical activity [ Time Frame: Measured at 1 year ] [ Designated as safety issue: No ]
  • Smoking cessation or reduction, if current tobacco smoker [ Time Frame: Measured at 1 year ] [ Designated as safety issue: No ]
  • Prescribed antiplatelet agents/anticoagulants, if coronary artery disease patient [ Time Frame: Measured at 1 year ] [ Designated as safety issue: No ]
  • Prescribed β- Blockers, if coronary artery disease patient [ Time Frame: Measured at 1 year ] [ Designated as safety issue: No ]
  • Prescribed ACE inhibitors, if post myocardial infarction patient [ Time Frame: Measured at 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Patients' satisfaction with care and health care utilization [ Time Frame: Measured at 1 year ] [ Designated as safety issue: No ]

Enrollment: 525
Study Start Date: May 2006
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Participants will receive a Cl intervention delivered by a nurse practitioner, a CHW, and the patient's physician, focusing on behavioral interventions to affect therapeutic lifestyle changes and medication adherence as well as the prescription and titration of medications.
Behavioral: Lifestyle Changes
Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
Drug: Antiplatelet Agents
Aspirin 81 mg q day
Other Name: Bayer, Ecotrin
Drug: Beta Blocker
Oral medication
Other Names:
  • Metoprolol
  • Toprol
  • Atenolol
  • Propranolol
Drug: ACE Inhibitors
Oral medications, recieved 1-2 times per day
Other Name: Lisinopril
Active Comparator: 2
Participants will receive a LI intervention providing feedback on CVD risk factors and guidelines to patients and their physicians.
Behavioral: Lifestyle Changes
Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
Drug: Antiplatelet Agents
Aspirin 81 mg q day
Other Name: Bayer, Ecotrin
Drug: Beta Blocker
Oral medication
Other Names:
  • Metoprolol
  • Toprol
  • Atenolol
  • Propranolol
Drug: ACE Inhibitors
Oral medications, recieved 1-2 times per day
Other Name: Lisinopril

Detailed Description:

BACKGROUND:

The study is based on the premise that a community-based participatory research partnership model, using a team of an advanced practice nurse case manager, community health worker (CHW), and physician can be translated into urban community clinics and improve the quality of care and reduce disparities in cardiovascular health in minority and other underserved populations. Despite well-publicized guidelines on the appropriate management of cardiovascular disease (CVD) and type 2 diabetes, implementation of CVD risk-reducing practices remains poor. In spite of the known benefit of lowering low-density lipoprotein cholesterol (LDL-C) levels below 100 mg/dl in persons with existing heart disease, as many as 50 to 70 percent of eligible CVD patients are not placed on lipid-lowering therapy by their providers and from 20 to 80 percent of patients do not achieve the goals of therapy. The benefits of controlling high blood pressure (HBP) are well established, yet national rates of HBP control remain at only 31 percent despite decades of provider and patient education. In addition, it is well established that control of glycemia, hyperlipidemia, and blood pressure reduce the risk of vascular complications in people with diabetes, 75 percent of whom die from some form of heart or blood vessel disease. This randomized trial will compare the clinical effectiveness and cost effectiveness of a CI intervention with a LI intervention in African American, and white low-income patients with known excessive CVD risk.

DESIGN NARRATIVE:

Eligible patients with CVD or type 2 diabetes will be randomly selected from two urban federally funded community clinics and randomly assigned to receive either 1) a Cl intervention delivered by a nurse practitioner, a CHW, and the patient's physician, focusing on behavioral interventions to affect therapeutic lifestyle changes and medication adherence as well as the prescription and titration of medications or 2) a LI intervention providing feedback on CVD risk factors and guidelines to patients and their physicians. Outcomes will be measured at baseline and one and two years. It is hypothesized that a higher proportion of patients in the Cl intervention group will achieve the treatment goals for lipid, blood pressure, and diabetes management, lifestyle behaviors and utilization of antiplatelet agent, beta blocker, and angiotensin converting enzyme (ACE) inhibitor therapies and that the Cl intervention will be cost-effective. Secondary outcomes include assessment of the impact of the Cl intervention model on patients' satisfaction with care and health care utilization. The increase in the percentage of high-risk women and men who receive recommended secondary prevention therapies and achieve goal levels could potentially result in a marked decrement in annual CVD mortality and health disparities if applied within primary care settings to populations with the characteristics of the target groups for this study.

  Eligibility

Ages Eligible for Study:   21 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Currently receiving medical care at Johns Hopkins University
  • African American or Caucasian and have diagnosed CVD, defined as a prior myocardial infarction, revascularization procedure for coronary disease, ischemic heart disease, stroke, or have diagnosed type 2 diabetes and not receiving any therapy
  • Have either no LDL-C in their medical record during the 12 months prior to study entry or have an LDL greater than or equal to 100 mg/dl on or off lipid lowering pharmacotherapy
  • Have either no blood pressure recorded in their medical record during the 12 months prior to study entry or a BP greater than 140/90 mmHg or greater than 130/80 mmHg if the participant is diabetic or has renal insufficiency
  • If the participant is diabetic he or she has to either have no HbA1c recorded during the 12 months prior to study entry or HbA1c of 7 percent or greater

Exclusion criteria:

  • A serious life-threatening noncardiac comorbidity with a life expectancy of less than 5 years
  • A serious physician-recorded psychiatric morbidity that would interfere with the study
  • Sufficient neurological impairment that would interfere with the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00241904

Locations
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
Johns Hopkins University
Investigators
Principal Investigator: Jerilyn Allen Johns Hopkins University School of Nursing
  More Information

No publications provided by Johns Hopkins University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jerilyn K. Allen, Professor, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00241904     History of Changes
Obsolete Identifiers: NCT00385619
Other Study ID Numbers: 335, R01HL082638, R01 HL82638
Study First Received: October 17, 2005
Last Updated: February 24, 2014
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Arteriosclerosis
Intracranial Arteriosclerosis
Brain Diseases
Atherosclerosis
Cardiovascular Diseases
Coronary Disease
Coronary Artery Disease
Diabetes Mellitus
Heart Diseases
Hypertension
Arterial Occlusive Diseases
Vascular Diseases
Myocardial Ischemia
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Intracranial Arterial Diseases
Cerebrovascular Disorders
Central Nervous System Diseases
Nervous System Diseases
Adrenergic beta-Antagonists
Angiotensin-Converting Enzyme Inhibitors
Platelet Aggregation Inhibitors
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors

ClinicalTrials.gov processed this record on July 28, 2014